Studies

  • Golimumab dose Optimisation to Adequate Levels to Achieve Response in Colitis GOAL-ARC is a nationwide multi-centred investigator initiated randomized control trial to evaluate the use of personalized Golimumab (GLM) dose adjustment in ulcerative colitis. The primary objective is to ascertain if dose adjustment of GLM, based......

  • IBD Cancer and Serious Infections in Europe     I-CARE is the first observational European prospective cohort study that will provide unique information (safety, efficacy, risk-benefit ratio, and healthcare costs) on the long-term use of recommended therapy in IBD, using a predefined standardized follow-up. These real world data will be used......

  • Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients. With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD......

  • STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for Crohn’s Disease. Ustekinumab (Stelara) is a monoclonal antibody against the common p40 subunit of IL-12 and IL-23. It has been licenced as a treatment for psoriasis for several years and......